Leukemia - Acute
AML not otherwise categorized
AML with Philadelphia chromosome
Reviewer: Daniela Mihova, M.D. (see Reviewers page)
Revised: 1 February 2013, last major update September 2012
Copyright: (c) 2001-2013, PathologyOutlines.com, Inc.
● Not part of WHO classification
● 1% of AML (Leuk Res 2004;28:579, Zhongguo Shi Yan Xue Ye Xue Za Zhi 2005;13:358), more common in bilineal, biphenotypic and acute basophilic leukemias
● Rarely is a secondary cytogenetic abnormality (Cancer Genet Cytogenet 2006;165:70)
● Compared to CML in blast crisis, has less frequent splenomegaly and peripheral basophilia, lower marrow cellularity and lower M/E ratios in marrow (Am J Clin Pathol 2007;127:642)
● Median survival 9 months
● Associated with poor prognosis in biphenotypic leukemia (Haematologica 1999;84:699)
● Philadelphia chromosome / translocation is t(9;22)(q34;q11), associated with CML (Wikipedia (Philadelphia chromosome))
● 44 year old man with dual presence of t(9;22) and inv(16) (Am J Clin Pathol 2006;125:260)
● Positive AML-M7 with extreme thrombocytosis and resistance to therapy (Ann Hematol 2004;83:381)
● Possibly imatinib, then allogeneic stem cell transplant (Eur J Haematol 2007;79:170)
● May occur in various AML subtypes
Fig A: hypercellular marrow (80%); fig B: mild increase in reticulin
Fig C: erythroid cells are dysplastic; fig D: CML
End of Leukemia - Acute > AML not otherwise categorized > AML with Philadelphia chromosome
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.
All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at [email protected] with any questions (click here for other contact information).